Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs
Executive Summary
Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.